Leqembi (Lecanemab-Irmb) for Alzheimer's

Overview
Leqembi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. It is specifically indicated for those in the mild cognitive impairment or mild dementia stage of the disease. Leqembi is also known by its drug name, lecanemab-irmb.

Leqembi belongs to the category of monoclonal antibodies. It is designed to target and reduce the buildup of beta-amyloid plaques in the brain, which are believed to contribute to the progression of Alzheimer’s disease. By reducing these plaques, Leqembi may help slow the cognitive decline associated with Alzheimer’s disease.

How do I take it?
Prescribing information states that Leqembi is administered as an intravenous infusion. Each infusion is administered once every two weeks and generally takes approximately one hour. It is important for this medication to be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Leqembi include infusion-related reactions, amyloid-related imaging abnormalities (ARIA, referring to changes seen in brain imaging) with microhemorrhages (small brain bleeds), edema (swelling due to fluid buildup in tissues), and effusion (abnormal accumulation of fluid in a body cavity or space), and headaches.

Rare but serious side effects may include serious intracerebral hemorrhages (brain bleeds greater than 1 centimeter) and severe cases of ARIA. Individuals with a specific genetic marker called APOE4 may have a higher risk of certain side effects, so discuss genetic testing with your doctor.

For more information about this treatment, visit:

Label: Leqembi — Lecanemab Injection, Solution — DailyMed

Leqembi — Drugs.com